VRTX
Price:
$450.97
Market Cap:
$116.14B
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clin...[Read more]
Industry
Biotechnology
IPO Date
1991-07-24
Stock Exchange
NASDAQ
Ticker
VRTX
According to Vertex Pharmaceuticals Incorporated’s latest financial reports and current stock price. The company's current ROE is -2.88%. This represents a change of 86.25% compared to the average of -1.55% of the last 4 quarters.
The mean historical ROE of Vertex Pharmaceuticals Incorporated over the last ten years is 5.16%. The current -2.88% ROE has changed -155.94% with respect to the historical average. Over the past ten years (40 quarters), VRTX's ROE was at its highest in in the December 2018 quarter at 34.96%. The ROE was at its lowest in in the June 2024 quarter at -24.32%.
Average
5.16%
Median
19.96%
Minimum
-67.38%
Maximum
47.28%
Discovering the peaks and valleys of Vertex Pharmaceuticals Incorporated ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 266.46%
Maximum Annual ROE = 47.28%
Minimum Annual Increase = -254.07%
Minimum Annual ROE = -67.38%
Year | ROE | Change |
---|---|---|
2023 | 20.59% | -13.77% |
2022 | 23.88% | 2.97% |
2021 | 23.19% | -25.71% |
2020 | 31.22% | 61.42% |
2019 | 19.34% | -59.10% |
2018 | 47.28% | 266.46% |
2017 | 12.90% | -254.07% |
2016 | -8.37% | -83.61% |
2015 | -51.08% | -24.19% |
2014 | -67.38% | 105.35% |
The current ROE of Vertex Pharmaceuticals Incorporated (VRTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
22.55%
5-year avg
23.64%
10-year avg
5.16%
Vertex Pharmaceuticals Incorporated’s ROE is less than BioMarin Pharmaceutical Inc. (6.22%), less than Sarepta Therapeutics, Inc. (11.83%), greater than Seagen Inc. (-16.53%), less than Alnylam Pharmaceuticals, Inc. (323.66%), greater than Intellia Therapeutics, Inc. (-51.97%), greater than Editas Medicine, Inc. (-80.13%), greater than Beam Therapeutics Inc. (-16.22%), greater than Ginkgo Bioworks Holdings, Inc. (-70.11%), greater than BioNTech SE (-2.38%), greater than Moderna, Inc. (-17.68%), less than Regeneron Pharmaceuticals, Inc. (16.85%), greater than Viking Therapeutics, Inc. (-12.73%), less than PTC Therapeutics, Inc. (48.38%), less than Reata Pharmaceuticals, Inc. (47.21%), greater than Intercept Pharmaceuticals, Inc. (-12.41%), less than Krystal Biotech, Inc. (6.34%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), greater than CRISPR Therapeutics AG (-12.15%), greater than Caribou Biosciences, Inc. (-45.46%), greater than Verve Therapeutics, Inc. (-35.23%),
Company | ROE | Market cap |
---|---|---|
6.22% | $12.25B | |
11.83% | $10.91B | |
-16.53% | $43.15B | |
323.66% | $31.59B | |
-51.97% | $1.46B | |
-80.13% | $201.42M | |
-16.22% | $2.07B | |
-70.11% | $412.70M | |
-2.38% | $27.12B | |
-17.68% | $15.82B | |
16.85% | $79.76B | |
-12.73% | $5.86B | |
48.38% | $3.33B | |
47.21% | $6.57B | |
-12.41% | $794.69M | |
6.34% | $5.48B | |
-71.78% | $7.58B | |
-12.15% | $4.09B | |
-45.46% | $182.92M | |
-35.23% | $410.62M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vertex Pharmaceuticals Incorporated using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vertex Pharmaceuticals Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Vertex Pharmaceuticals Incorporated's ROE?
How is the ROE calculated for Vertex Pharmaceuticals Incorporated (VRTX)?
What is the highest ROE for Vertex Pharmaceuticals Incorporated (VRTX)?
What is the 3-year average ROE for Vertex Pharmaceuticals Incorporated (VRTX)?
What is the 5-year average ROE for Vertex Pharmaceuticals Incorporated (VRTX)?
How does the current ROE for Vertex Pharmaceuticals Incorporated (VRTX) compare to its historical average?